Advertisement

Pharmaceutical Chemistry Journal

, Volume 52, Issue 10, pp 844–849 | Cite as

Synthesis and Neurotropic Activity of New Condensed Pyrano[4,3-b]-Pyridines Derivatives

  • V. V. Dabaeva
  • M. R. Bagdasaryan
  • Sh. Sh. Dashyan
  • I. A. Dzhagatspanyan
  • I. M. Nazaryan
  • A. G. Akopyan
  • R. G. Paronikyan
Article
  • 24 Downloads

Methods for synthesizing new condensed pyrano[4, 3-b]pyridine derivatives from 2-methyl-2-ethyltetrahydropyran-4-one were developed. The neurotropic activities of the compounds were studied.

Keywords

synthesis pyrano[3″,4″:5′,6′]pyrido[3′,2′:4,5]thieno[3,2-d]pyrimidine neurotropic activity 

References

  1. 1.
    V. V. Dabaeva, M. R. Bagdasaryan, Zh. V. Kazaryan, et al., Khim.-farm. Zh., 49(12), 87 – 90 (2015); Pharm. Chem. J., 49(12), 830 – 833 (2015).Google Scholar
  2. 2.
    V. V. Dabaeva, M. R. Bagdasaryan, A. S. Noravyan, et al., Khim.-farm. Zh., 46(5), 11 – 13 (2012); Pharm. Chem. J., 46(5), 271 – 273 (2012).Google Scholar
  3. 3.
    V. V. Dabaeva, M. R. Bagdasaryan, A. S. Noravyan, et al., Khim.-farm. Zh., 47(3), 12 – 14 (2013); Pharm. Chem. J., 47(3), 135 – 138 (2013).Google Scholar
  4. 4.
    I. N. Nazarov, I. V. Torgov, and D. N. Terekhova, Izv. Akad. Nauk SSSR, Otd. Khim. Nauk, 50 – 55 (1943).Google Scholar
  5. 5.
    V. V. Dabaeva, M. R. Bagdasaryan, and A. S. Naravyan, Khim. Geterotsikl. Soedin., 47(5), 770 – 775; Chem. Heterocycl. Compd., 47(5), 639 – 643 (2011).Google Scholar
  6. 6.
    European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes, European Treaty Series No. 123, Strasbourg, France (1986), p. 11.Google Scholar
  7. 7.
    H. G. Vogel and W. H. Vogel (eds.), Drug Discovery and Evaluation. Pharmacological Assays, Springer, Berlin, New York (1997), pp. 246 – 350.CrossRefGoogle Scholar
  8. 8.
    A. P. Mkrtchyan, S. G. Kazaryan, A. S. Noravyan, et al., Khim.-farm. Zh., 32(9), 15 – 19 (1998); Pharm. Chem. J., 32(9), 469 – 473 (1998).Google Scholar
  9. 9.
    I. A. Dzhagatspanyan and A. B. Asryan, Eksp. Klin. Farmakol., 1, 5 – 8 (1994).Google Scholar
  10. 10.
    S. Pelow and S. E. File, Pharmacol. Biochem. Behav., 24(3), 525 – 529 (1986).CrossRefGoogle Scholar
  11. 11.
    J. Buresh and O. Bureshova, J. Comp. Physiol. Psychol., 756, 286 – 272 (1963).Google Scholar
  12. 12.
    G. Dawson and M. D. Tricklebank, Trends Pharmacol. Sci., 16, 33 – 36 (1995).CrossRefGoogle Scholar
  13. 13.
    S. E. File, Behav. Brain Res., 58, 199 – 202 (1993).CrossRefGoogle Scholar
  14. 14.
    A. Covanis, A. K. Gupta, and P. M. Jeavons, Epilepsia, 23, 693 – 720 (1982).CrossRefGoogle Scholar
  15. 15.
    J. T. Litchfield and F. Wilcoxon, J. Pharmacol. Exp. Ther., 96, 99 – 113 (1949).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • V. V. Dabaeva
    • 1
  • M. R. Bagdasaryan
    • 1
  • Sh. Sh. Dashyan
    • 1
  • I. A. Dzhagatspanyan
    • 2
  • I. M. Nazaryan
    • 1
  • A. G. Akopyan
    • 1
  • R. G. Paronikyan
    • 1
  1. 1.A. L. Mnjoyan Institute of Fine Organic Chemistry, Scientific and Technological Center of Organic and Pharmaceutical ChemistryNational Academy of Sciences of ArmeniaYerevanArmenia
  2. 2.E. G. Gabrielyan Scientific Centre for Expertise of Drugs and Medical TechnologiesYerevanArmenia

Personalised recommendations